We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.175 | 0.15 | 0.20 | 377,843 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -859k | -0.0010 | -1.70 | 1.43M |
TIDMNFX
RNS Number : 7253R
Nuformix PLC
09 November 2021
9 November 2021
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Alastair Riddell, currently Non-Executive Chairman, will assume the role of Executive Chairman with effect from 1 December 2021.
Enquiries:
Nuformix plc via Walbrook Dr Alastair Riddell, Non-Executive Chairman Dr Anne Brindley, CEO Allenby Capital Limited +44 (0) 20 3328 5656 Nick Athanas / George Payne (Corporate Finance) Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) Walbrook PR nuformix@walbrookpr.com or +44 (0)20 7933 8780 Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOABPBBTMTMMTIB
(END) Dow Jones Newswires
November 09, 2021 02:00 ET (07:00 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions